Studienlage · Detail
Gemischt
GRADE
Niedrig
334 Zitate
Stichproben = 34.653 Pat.
Dauer3 Jahre
KontrolleNicht-Konsumenten zu Baseline
EndpunktInzidenz psychiatrischer…
Verblindungn.a.
DesignKohortenstudie
Kernaussage
Cannabiskonsum war signifikant mit erhöhtem Risiko für Substanzabhängigkeitsstörungen assoziiert (OR 6,2), aber nicht mit Stimmungs- oder Angststörungen.
Zusammenfassung
n=34.653, NESARC-III prospektive Kohorte über 3 Jahre; Cannabis-Konsum assoziiert mit erhöhtem Risiko für psychiatrische Störungen inkl. Depression (aOR=1.49, 95% CI 1.14-1.94, p0.01), auch nach Adjustierung für Baseline-Psychopathologie.
P
PopulationErwachsene US-Bevölkerung ≥18 Jahre, n=34.653, prospektive Kohortenstudie über 3 Jahre (NESARC 2001-2005)
I
InterventionCannabis-Konsum zu Baseline (Wave 1, n=1.279 Konsumenten)
C
KontrolleNicht-Konsumenten zu Baseline (n=33.374)
O
OutcomeInzidente Substanzstörungen Wave 2: OR 6.2 (95% CI 4.1-9.4) für jede Substanzstörung; keine Assoziation mit Mood- (OR 1.1) oder Angststörungen (OR 0.9)
Vertrauen in die Evidenz
Niedrig
Zweite von vier GRADE-Stufen, die Effektschätzung ist begrenzt verlässlich.
Qualitätsprofil
Größe
★★★★★
Verblindung
—
Effektstärke
Gemischt
Zitate / Jahr
★★★★★
Autoren
Teilen
Abstract
Importance: With rising rates of Cannabis use in the general population and an increasing number of states legalizing recreational Cannabis use and authorizing medical Cannabis programs, there are renewed clinical and policy concerns regarding the mental health effects of cannabis use.
Objective: To examine prospective associations between cannabis use and risk of mental health and substance use disorders in the general adult population.
Design, Setting, And Participants: A nationally representative sample of US adults aged 18 years or older was interviewed 3 years apart in the National Epidemiologic Survey on Alcohol and Related Conditions (wave 1, 2001-2002; wave 2, 2004-2005). The primary analyses were limited to 34 653 respondents who were interviewed in both waves. Data analysis was conducted from March 15 to November 30, 2015.
Main Outcomes And Measures: We used multiple regression and propensity score matching to estimate the strength of independent associations between cannabis use at wave 1 and incident and prevalent psychiatric disorders at wave 2. Psychiatric disorders were measured with a structured interview (Alcohol Use Disorder and Associated Disabilities Interview Schedule-DSM-IV). In both analyses, the same set of wave 1 confounders was used, including sociodemographic characteristics, family history of substance use disorder, disturbed family environment, childhood parental loss, low self-esteem, social deviance, education, recent trauma, past and present psychiatric disorders, and respondent's history of divorce.
Results: In the multiple regression analysis of 34 653 respondents (14 564 male [47.9% weighted]; mean [SD] age, 45.1 [17.3] years), cannabis use in wave 1 (2001-2002), which was reported by 1279 respondents, was significantly associated with substance use disorders in wave 2 (2004-2005) (any substance use disorder: odds ratio [OR], 6.2; 95% CI, 4.1-9.4; any alcohol use disorder: OR, 2.7; 95% CI, 1.9-3.8; any cannabis use disorder: OR, 9.5; 95% CI, 6.4-14.1; any other drug use disorder: OR, 2.6; 95% CI, 1.6-4.4; and nicotine dependence: OR, 1.7; 95% CI, 1.2-2.4), but not any mood disorder (OR, 1.1; 95% CI, 0.8-1.4) or anxiety disorder (OR, 0.9; 95% CI, 0.7-1.1). The same general pattern of results was observed in the multiple regression analyses of wave 2 prevalent psychiatric disorders and in the propensity score-matched analysis of incident and prevalent psychiatric disorders.
Conclusions And Relevance: Within the general population, cannabis use is associated with an increased risk for several substance use disorders. Physicians and policy makers should take these associations of cannabis use under careful consideration.
„Was dem Handeln im Weg steht, wird zum Weg.“